Gerresheimer AG (GRRMY)
OTCMKTS · Delayed Price · Currency is USD
7.17
+0.24 (3.49%)
At close: Nov 26, 2025
Gerresheimer AG Revenue
Gerresheimer AG had revenue of 560.68M EUR in the quarter ending August 31, 2025, with 12.47% growth. This brings the company's revenue in the last twelve months to 2.25B, up 11.83% year-over-year. In the fiscal year ending November 30, 2024, Gerresheimer AG had annual revenue of 2.04B with 2.28% growth.
Revenue (ttm)
2.25B EUR
Revenue Growth
+11.83%
P/S Ratio
0.39
Revenue / Employee
185.33K EUR
Employees
12,142
Market Cap
1.04B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Nov 30, 2024 | 2.04B | 45.42M | 2.28% |
| Nov 30, 2023 | 1.99B | 173.39M | 9.54% |
| Nov 30, 2022 | 1.82B | 319.09M | 21.30% |
| Nov 30, 2021 | 1.50B | 79.22M | 5.58% |
| Nov 30, 2020 | 1.42B | 26.53M | 1.91% |
| Nov 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 122.89M |
| Zomedica | 29.45M |
| Silence Therapeutics | 25.83M |
| Northwest Biotherapeutics | 937.00K |